Lille & Paris, France — February 10, 2026: 4Moving Biotech (4MB), a clinical-stage biotechnology company and spin-off of 4P-Pharma, announced the successful closing of a €12 million financing round to accelerate development of its first-in-class disease-modifying osteoarthritis drug (DMOAD) targeting knee osteoarthritis. The structured funding round—backed by private investors and family offices through a mix of equity and loans—extends the company’s financial runway to achieve a critical Phase 2a proof-of-concept inflection point.
Science Significance
4MB’s lead therapeutic program focuses on a first-in-class DMOAD designed to modify the structural progression of knee osteoarthritis rather than merely alleviate symptoms. Osteoarthritis is characterized by cartilage degradation, inflammation, and joint degeneration, yet current treatments largely rely on pain management or surgical intervention. By targeting disease biology and inflammatory pathways, the investigational therapy aims to slow or halt joint destruction, representing a transformative shift in musculoskeletal drug development. The molecule is being evaluated through the INFLAM-MOTION Phase 2a clinical study, including a recently expanded transatlantic trial footprint, supporting translational validation of its regenerative and anti-inflammatory mechanism.
Regulatory Significance
Advancement of the Phase 2a program positions 4MB for upcoming regulatory agency interactions and clinical development consultations. Achieving proof-of-concept data is a pivotal milestone required to guide dose optimization, endpoint validation, and future pivotal trial design. The company’s clinical strategy aligns with global regulatory expectations for disease-modifying therapies in chronic degenerative conditions, including demonstration of structural joint benefit alongside functional outcomes. Continued progression will require adherence to Good Clinical Practice (GCP) governance, investigational safety monitoring, and regulatory documentation frameworks supporting eventual marketing authorization pathways.
Business Significance
Advertisement
The €12 million financing reflects strong investor confidence in both the DMOAD program and 4P-Pharma’s drug regeneration start-up studio model. Investors participated directly at the subsidiary level, reinforcing strategic alignment and long-term value creation. The funding builds upon prior non-dilutive public support, including a €7.6 million France 2030 i-Démo grant, bringing total capital raised by 4MB to approximately €30 million. This blended financing structure strengthens operational sustainability while enabling execution of near-term clinical milestones, partnership exploration, and future licensing optionality as data maturity advances.
Patients’ Significance
Knee osteoarthritis affects an estimated 374 million patients worldwide, representing one of the most prevalent and disabling chronic musculoskeletal disorders. Current therapies offer limited disease modification, often leading to progressive mobility loss, chronic pain, and eventual joint replacement surgery. A successful DMOAD could delay or prevent surgical intervention, preserve joint function, and improve long-term quality of life. By addressing structural degeneration rather than symptoms alone, the investigational therapy holds potential to redefine the treatment paradigm for patients facing limited therapeutic innovation.
Policy Significance
The financing underscores growing policy and funding emphasis on chronic disease innovation and regenerative therapeutics. Public–private funding collaboration—combining venture investment with government grant support—reflects national and regional strategies to accelerate development of high-impact therapies addressing aging-related diseases. Osteoarthritis represents a major socioeconomic burden due to disability, healthcare utilization, and productivity loss, reinforcing policy prioritization of disease-modifying interventions capable of reducing long-term healthcare system strain.
With €12 million in new capital secured, 4Moving Biotech is positioned to advance its first-in-class osteoarthritis DMOAD through critical clinical inflection milestones. The financing strengthens execution of its Phase 2a study, supports regulatory engagement preparation, and enhances long-term partnership potential. As disease-modifying therapies remain a major unmet need in musculoskeletal medicine, the program represents a significant step toward transforming osteoarthritis treatment through innovative regenerative pharmacology and precision clinical development.
Source: 4Moving Biotech press release
